Nasdaq Rytm News Today

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $50.00 price target on the stock. Needham & Company LLC’s price target would suggest a potential upside […]

Needham & Company LLC reiterated their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a research report released on Friday morning, Benzinga reports. They currently have a $50.00 target price on the stock. A number of other equities analysts also recently commented on RYTM. The Goldman Sachs Group upped their target […]

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price lowered by Wells Fargo & Company from $53.00 to $52.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an overweight rating on the stock. A number of other equities analysts have also recently weighed in on the stock. Needham & Company […]

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s share price was down 4.4% on Thursday . The stock traded as low as $43.43 and last traded at $46.68. Approximately 90,505 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 686,012 shares. The stock had previously closed at $48.81. […]

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) traded down 4.4% during trading on Thursday . The stock traded as low as $43.43 and last traded at $46.68. 90,505 shares traded hands during trading, a decline of 87% from the average session volume of 686,012 shares. The stock had previously closed at $48.81. Analyst Upgrades […]

-- Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) EVP Yann Mazabraud sold 1,594 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $51.38, for a total value of $81,899.72. Following the completion of the transaction, the executive vice president now directly owns 7,702 […]

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) CFO Hunter C. Smith sold 1,209 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $51.38, for a total transaction of $62,118.42. Following the transaction, the chief financial officer now directly owns 80,413 shares in […]

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) EVP Yann Mazabraud sold 1,594 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $51.38, for a total value of $81,899.72. Following the sale, the executive vice president now owns 7,702 shares of the company’s stock, […]

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) insider Joseph Shulman sold 1,089 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $50.01, for a total transaction of $54,460.89. Following the sale, the insider now directly owns 30 shares of the […]